Biological therapy for systemic vasculitis: A systematic review
2013.11.19
|
The epidemiology of atherosclerotic cardiovascular disease among patients with SLE: A systematic review
2013.8.23
|
Vitamin D in Systemic Lupus Erythematosus Modest Association With Disease Activity and the Urine Protein-to-Creatinine Ratio
2013.8.1
|
Safety and efficacy of canakinumab in Japanese patients with phenotypes of cryopyrin-associated periodic syndrome
as established in the first open-label, phase-3 pivotal study (24-week results)
2013.7.5
|
Etanercept Improves Lipid Profile and Oxidative Stress Measures in Patients with Juvenile Idiopathic Arthritis
2013.6.28
|
Effectiveness and safety
of a second and third biological agent after failing etanercept in juvenile
idiopathic arthritis: results from the Dutch National ABC Register
2013.6.1
|
Incidence of Selected
Opportunistic Infections Among Children With Juvenile Idiopathic Arthritis
2013.5.16
|
Tumour necrosis factor-blocking agents in persistent oligoarticular juvenile idiopathic arthritis
2013.4.22
|
Randomized Trial of Tocilizumab in Systemic Juvenile Idiopathic Arthritis
2013.1.28
|
Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis
2013.1.8
|
Dyslipidemia and Changes in Lipid Profiles Associated With Rheumatoid Arthritis and Initiation of Anti–Tumor Necrosis Factor Therapy
2012.10.15
|
Consensus Treatment Plans for New-Onset,Systemic Juvenile Idiopathic Arthritis
2012.9.13
|